Hillstream loach

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Retrieved on: 
Monday, September 11, 2023
Hepatitis, Mouth, Ascending cholangitis, Hepatology, Liver disease, PBC, Biotechnology, Atopic dermatitis, US, Primary biliary cholangitis, Patient, Liver, Cheek, Alcoholic liver disease, IND, Chronic kidney disease, Skin, Pharmaceutical industry, Hillstream loach

BRIDGEWATER, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancer announces an exclusive option agreement to acquire a clinical stage asset, AV104, with a recently approved IND. AV104 has a dual mechanism of action by affecting multiple receptors, known to suppress chronic, debilitating pruritis or “uncontrollable itching”. The Company intends to first seek approval in an orphan disease for the treatment of moderate to severe cholestatic pruritis in patients with primary biliary cholangitis (PBC), a rare form of liver disease with no known cure in which more than 70% of patients suffer from chronic pruritis.

Key Points: 
  • AV104 has a dual mechanism of action by affecting multiple receptors, known to suppress chronic, debilitating pruritis or “uncontrollable itching”.
  • When the itch circuitry is imbalanced in diseased conditions, pharmacological intervention can help suppress this phenomenon which occurs in patients suffering from chronic pruritis.
  • Chronic pruritis is significant in liver diseases as well as chronic kidney diseases, hemodialysis and atopic dermatitis.
  • “This exclusive option allows the company to bring a clinical-stage asset into the organization as we shift into a patient-focused biotechnology organization.

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

Retrieved on: 
Friday, September 8, 2023
Biotechnology, Hillstream loach, Conference, Pharmaceutical industry, Nightclub

BRIDGEWATER, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers with immuno-oncology targeted novel biologics, today announced that it will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, being held in person and virtually from September 11-13, 2023.

Key Points: 
  • BRIDGEWATER, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers with immuno-oncology targeted novel biologics, today announced that it will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, being held in person and virtually from September 11-13, 2023.
  • *Please note that Company presentation date and time are subject to change.
  • Attendees may refer to the program agenda for more information.
  • Once the presentation becomes available on-demand, registered attendees can submit their Q&As for the Company.

Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023

Retrieved on: 
Wednesday, August 9, 2023
HER3, Biotechnology, Knob, Ferroptosis, Conference, Pharmaceutical industry, Hillstream loach

Company recently announced license and collaboration expansions for next-gen multispecific antibodies for solid tumors with lead HER2/HER3 program, HSB-3215, in collaboration with OmniAb, Inc. and Minotaur Therapeutics, Inc.

Key Points: 
  • Company recently announced license and collaboration expansions for next-gen multispecific antibodies for solid tumors with lead HER2/HER3 program, HSB-3215, in collaboration with OmniAb, Inc. and Minotaur Therapeutics, Inc.
    BRIDGEWATER, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced that it will be attending the Annual Sidoti Micro-Cap Virtual Conference being held on August 16-17, 2023.
  • “We’ve made a lot of progress since we’ve announced the strategic reprioritization of our drug pipeline making this an opportune time to share updates with the investment community,” says Randy Milby, CEO of Hillstream.
  • This will in turn complement Hillstream’s HSB-3215 program.
  • To schedule a meeting with the management team or view the presentation, please send an email to [email protected] or visit https://www.meetmax.com/sched/event_96493/investor_reg_new.html?attendee... .

Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215

Retrieved on: 
Thursday, July 20, 2023
Bispecific monoclonal antibody, Antigen, Partnership, HER3, The central science, HER2, Neoplasm, Knob, Antibody, CDR, US, Animal, Epitope, CDR3, Vaccine, Hillstream loach, Minotaur, Collaboration, IND

BRIDGEWATER, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (“Hillstream”, the “Company”) today announced the expansion of its collaboration with Minotaur Therapeutics, Inc. (“Minotaur”) and its license agreement with OmniAb, Inc. (“OmniAb”) to advance the development of next generation targeted Knob biologics (PicobodiesTM) against HER3 and a new undisclosed oncology target. Hillstream will collaborate with Minotaur using OmniAb’s “OmniTaur™” technology to discover targeted biotherapeutic Picobodies complementing Hillstream’s most advanced program, HSB-3215, a HER2/HER3 bispecific antibody (BsAb).

Key Points: 
  • As a diverse group of molecules, BsAbs recognize distinct epitopes on two different antigens, in the case of HSB-3215, HER2 and HER3.
  • These validated targets, belong to the ERBB receptor tyrosine kinase family and are exploited by cancer cells to promote oncogenesis.
  • This conceivable “multi-specific” capacity of PicobodiesTM could more efficiently target multiple cell surface portions compared to known or existing biologics.
  • Hillstream is now poised to develop a novel technology for creating multiple proteins to enhance targeted cancer immunotherapy.”

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

Retrieved on: 
Monday, July 10, 2023
Bispecific monoclonal antibody, Monoclonal antibody, Antigen, Bausch Health, Therapy, HER3, Critical, HER2, Neoplasm, Salix Pharmaceuticals, Biotechnology, Trastuzumab, Cancer, Daiichi Sankyo, Bystander effect, Rutgers University, US, Acquisition, Patient, EGFR, Minotaur, Epitope, Spacecraft, PD-1, Sanofi, IND, Metastasis, Vaccine, Pharmaceutical industry, Amgen, Pharmacy, Chiesi Farmaceutici, Hillstream loach, Willow

BRIDGEWATER, N.J., July 10, 2023 (GLOBE NEWSWIRE) --  Hillstream BioPharma (Nasdaq: HILS) a biotechnology company developing innovative therapeutic candidates targeting drug resistant and devastating cancers that can make a difference in patients’ lives, today announced a strategic reprioritization of its pipeline and provided a corporate update. The strategic assessment took into account, the pipeline’s near-term value creation opportunity and other factors. Hillstream will focus its pipeline on advancing novel oncology assets with the greatest potential and strong competitive profiles to address unmet needs across multiple solid tumors, such as bispecific antibodies and ADCs targeting novel conformational epitopes on high value validated targets, HER2 and HER3, with a more potent Bystander Effect.

Key Points: 
  • Bispecific antibodies (BsAbs) refer to a diverse group of molecules that recognize distinct epitopes on two different antigens, such as HER2 and HER3.
  • HER2, an extensively studied and validated target, has multiple approved therapeutics for solid tumors.
  • Hillstream’s lead asset, HSB-3215 is designed as a bispecific humanized immunoglobulin containing two arms targeting the extracellular domains of HER2 and HER3.
  • “I am thrilled to join Hillstream and look forward to working alongside the team as we further our development programs.

Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers

Retrieved on: 
Thursday, July 6, 2023
Antigen, ErbB, HER3, HER2, Biotechnology, Trastuzumab, Cancer, Lung cancer, Antibody, Charles, Daiichi Sankyo, Epitope, ADC, Spacecraft, Ovarian cancer, Stomach, Breast cancer, Vaccine, Hillstream loach

BRIDGEWATER, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using immuno-oncology targeted novel biologics, today announced the signing of an exclusive agreement with Applied Biomedical Science Institute (ABSI) to license technology for human antibodies targeting novel HER2 and HER3 Conformational Epitopes. The goal is to develop proprietary multi-format biologics, including bi-specific antibodies, and antibody drug conjugates (ADCs). The HER2/HER3 binding ADC is targeted to have a high drug-to-antibody ratio which should increase the anti-tumoral efficacy with an enhanced bystander killing effect. Hillstream intends to combat drug resistant cancers such as HER2-positive metastatic breast cancer, gastric cancer, lung cancer and ovarian cancer.

Key Points: 
  • The goal is to develop proprietary multi-format biologics, including bi-specific antibodies, and antibody drug conjugates (ADCs).
  • Hillstream intends to combat drug resistant cancers such as HER2-positive metastatic breast cancer, gastric cancer, lung cancer and ovarian cancer.
  • HER2 is also one of the most validated antigens for antibody drug conjugates (ADCs) to treat HER2 positive cancers with two approved antibodies, Roche/Genentech’s KADCYLA® and Daiichi Sankyo/AstraZeneca’s ENHERTU®.
  • The Applied Biomedical Science Institute has developed technology to target novel functional epitopes of the cancer targets HER2 and HER3.

Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson

Retrieved on: 
Monday, May 15, 2023
First American Corporation, Biotechnology, California State University, Cancer, Ferroptosis, Fisker Automotive, CXO, Research, Certified Public Accountant, Accounting, Patient, CFO, Psychic Friends Network, Management, Hillstream loach

“Kelly has served as a CFO and brings expertise in partnering negotiations and business development,” said Randy Milby, Chairman and CEO of Hillstream.

Key Points: 
  • “Kelly has served as a CFO and brings expertise in partnering negotiations and business development,” said Randy Milby, Chairman and CEO of Hillstream.
  • Kelly Anderson currently serves as Chief Executive Officer of CXO Executive Solutions, a specialized executive talent solutions company.
  • Mrs. Anderson previously served in senior financial executive posts at companies including Mavenlink (now known as Kantata), Ener-Core, Fisker Automotive, T3 Motion and The First American Corporation.
  • In addition, Mrs. Anderson currently serves as on the board of AgEagle Aerial Systems Inc., Tomi Environmental Solutions and Concierge Technologies and was previously a member of the board of directors of Marygold Companies, Guardion Health Sciences and Psychic Friends Network.

Hillstream BioPharma Announces Closing of Public Offering of Common Stock

Retrieved on: 
Tuesday, May 2, 2023
Biotechnology, ThinkEquity, Sale, Ferroptosis, Prospectus, State Street, Hillstream loach, Pharmaceutical industry, Security (finance)

BRIDGEWATER, N.J., May 02, 2023 (GLOBE NEWSWIRE) --  Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced the closing of its previously announced public offering of common stock.

Key Points: 
  • BRIDGEWATER, N.J., May 02, 2023 (GLOBE NEWSWIRE) --  Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced the closing of its previously announced public offering of common stock.
  • Hillstream sold 5,300,000 shares of its common stock at a public offering price of $0.50 per share for gross proceeds of $2,650,000 before deducting underwriting discounts and offering expenses.
  • In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 795,000 shares of common stock to cover over-allotments, if any, at the public offering price, less the underwriting discount.
  • The final prospectus supplement relating to the offering was filed with the SEC and is available on the SEC's website at http://www.sec.gov.

Hillstream BioPharma Announces Pricing of Public Offering

Retrieved on: 
Friday, April 28, 2023
Telephone, Biotechnology, ThinkEquity, Ferroptosis, Free File, Hillstream loach, Sale, Prospectus, State Street, S-3, Form, Life insurance

BRIDGEWATER, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced the pricing of an underwritten public offering of 5,300,000 shares of its common stock.

Key Points: 
  • BRIDGEWATER, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced the pricing of an underwritten public offering of 5,300,000 shares of its common stock.
  • Each share is being sold to the public at a price of $0.50 for gross proceeds of $2,650,000, before deducting underwriting discounts and offering expenses.
  • In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 795,000 shares to cover over-allotments at the public offering price, less the underwriting discount.
  • The offering is expected to close on May 2, 2023, subject to satisfaction of customary closing conditions.

Hillstream BioPharma Announces Proposed Public Offering

Retrieved on: 
Thursday, April 27, 2023
Telephone, Biotechnology, ThinkEquity, Ferroptosis, SEC filing, Hillstream loach, Sale, Prospectus, State Street, Form, Life insurance

ThinkEquity is acting as sole book-running manager for the offering.

Key Points: 
  • ThinkEquity is acting as sole book-running manager for the offering.
  • The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • The offering will be made only by means of a written prospectus.
  • A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been or will be filed with the SEC on its website at www.sec.gov .